Collaboration Expected to Generate High-Paying Jobs in Michigan

ANN ARBOR, Mich., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the 30th patient has been treated in the Company's U.S. Phase IIb RESTORE-CLI clinical trial. This milestone marks the first step toward interim

ANN ARBOR, Mich., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) ("Aastrom" or the "Company"), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that its Board of

Aastrom Preparing to Begin Phase 3 Clinical Trial in Q4 2011

Accomplished Industry Veteran Brings Extensive History of Successful Corporate Development, Fundraising and Capital Management to Aastrom

Experienced Senior Sales Professional Brings Wealth of Marketing, Strategic Planning and Brand Management Expertise to Aastrom

Globally Recognized Industry Veterans Bring Extensive R&D and Product Development Experience in Regenerative Medicine and Multiple Therapeutic Areas

ANN ARBOR, Mich., May 25, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced a collaborative agreement with CPC Clinical Research

ANN ARBOR, Mich., June 27, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it plans to exchange for common stock up to

ANN ARBOR, Mich., March 25, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded, patient specific cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the company will hold its 2011 Annual Meeting of